Journal article
Prevalence of Anti-infliximab Antibodies and Their Associated Co-factors in Children with Refractory Arthritis and/or Uveitis: A Retrospective Longitudinal Cohort Study.
- Aeschlimann FA From the Department of Rheumatology, University Children's Hospital, Zurich; RehaClinic Bad Zurzach, Bad Zurzach; Department of Pediatrics, Ostschweizer Kinderspital, St. Gallen, Switzerland; Laboratory for Biologicals, Sanquin; Department of Immunopathology, Sanquin Research; Landsteiner Academic Medical Centre, Amsterdam, the Netherlands; Department of Pediatrics, Kantonsspital Winterthur, Winterthur, Switzerland.
- Angst F From the Department of Rheumatology, University Children's Hospital, Zurich; RehaClinic Bad Zurzach, Bad Zurzach; Department of Pediatrics, Ostschweizer Kinderspital, St. Gallen, Switzerland; Laboratory for Biologicals, Sanquin; Department of Immunopathology, Sanquin Research; Landsteiner Academic Medical Centre, Amsterdam, the Netherlands; Department of Pediatrics, Kantonsspital Winterthur, Winterthur, Switzerland.
- Hofer KD From the Department of Rheumatology, University Children's Hospital, Zurich; RehaClinic Bad Zurzach, Bad Zurzach; Department of Pediatrics, Ostschweizer Kinderspital, St. Gallen, Switzerland; Laboratory for Biologicals, Sanquin; Department of Immunopathology, Sanquin Research; Landsteiner Academic Medical Centre, Amsterdam, the Netherlands; Department of Pediatrics, Kantonsspital Winterthur, Winterthur, Switzerland.
- Cannizzaro Schneider E From the Department of Rheumatology, University Children's Hospital, Zurich; RehaClinic Bad Zurzach, Bad Zurzach; Department of Pediatrics, Ostschweizer Kinderspital, St. Gallen, Switzerland; Laboratory for Biologicals, Sanquin; Department of Immunopathology, Sanquin Research; Landsteiner Academic Medical Centre, Amsterdam, the Netherlands; Department of Pediatrics, Kantonsspital Winterthur, Winterthur, Switzerland.
- Schroeder-Kohler S From the Department of Rheumatology, University Children's Hospital, Zurich; RehaClinic Bad Zurzach, Bad Zurzach; Department of Pediatrics, Ostschweizer Kinderspital, St. Gallen, Switzerland; Laboratory for Biologicals, Sanquin; Department of Immunopathology, Sanquin Research; Landsteiner Academic Medical Centre, Amsterdam, the Netherlands; Department of Pediatrics, Kantonsspital Winterthur, Winterthur, Switzerland.
- Lauener R From the Department of Rheumatology, University Children's Hospital, Zurich; RehaClinic Bad Zurzach, Bad Zurzach; Department of Pediatrics, Ostschweizer Kinderspital, St. Gallen, Switzerland; Laboratory for Biologicals, Sanquin; Department of Immunopathology, Sanquin Research; Landsteiner Academic Medical Centre, Amsterdam, the Netherlands; Department of Pediatrics, Kantonsspital Winterthur, Winterthur, Switzerland.
- van der Kleij D From the Department of Rheumatology, University Children's Hospital, Zurich; RehaClinic Bad Zurzach, Bad Zurzach; Department of Pediatrics, Ostschweizer Kinderspital, St. Gallen, Switzerland; Laboratory for Biologicals, Sanquin; Department of Immunopathology, Sanquin Research; Landsteiner Academic Medical Centre, Amsterdam, the Netherlands; Department of Pediatrics, Kantonsspital Winterthur, Winterthur, Switzerland.
- Rispens T From the Department of Rheumatology, University Children's Hospital, Zurich; RehaClinic Bad Zurzach, Bad Zurzach; Department of Pediatrics, Ostschweizer Kinderspital, St. Gallen, Switzerland; Laboratory for Biologicals, Sanquin; Department of Immunopathology, Sanquin Research; Landsteiner Academic Medical Centre, Amsterdam, the Netherlands; Department of Pediatrics, Kantonsspital Winterthur, Winterthur, Switzerland.
- Saurenmann RK From the Department of Rheumatology, University Children's Hospital, Zurich; RehaClinic Bad Zurzach, Bad Zurzach; Department of Pediatrics, Ostschweizer Kinderspital, St. Gallen, Switzerland; Laboratory for Biologicals, Sanquin; Department of Immunopathology, Sanquin Research; Landsteiner Academic Medical Centre, Amsterdam, the Netherlands; Department of Pediatrics, Kantonsspital Winterthur, Winterthur, Switzerland. traudel.saurenmann@kispi.uzh.ch.
- 2017-01-17
Published in:
- The Journal of rheumatology. - 2017
ANTICHIMERIC ANTIBODIES
INFLIXIMAB
INFUSION REACTIONS
JUVENILE IDIOPATHIC ARTHRITIS
UVEITIS
Antibodies
Antirheumatic Agents
Arthritis, Juvenile
Child
Child, Preschool
Female
Humans
Infant
Infliximab
Longitudinal Studies
Male
Retrospective Studies
Seroepidemiologic Studies
Uveitis
English
OBJECTIVE
Infliximab (IFX) is a monoclonal tumor necrosis factor-α-inhibiting antibody used in children with refractory arthritis and uveitis. Immunogenicity is associated with a lack of clinical response and infusion reactions in adults; data on immunogenicity in children treated with IFX for rheumatic diseases are scarce. We aimed to describe the prevalence of anti-IFX antibodies and determine co-factors associated with anti-IFX antibodies in children with inflammatory rheumatic and ocular diseases.
METHODS
Consecutive children treated between August 2009 and August 2012 with IFX at our department were included. Blood samples were collected every 6 months before IFX infusion and tested for anti-IFX antibodies by radioimmunoassay. Patients' charts were retrospectively reviewed for clinical features and analyzed for associations with anti-IFX antibodies.
RESULTS
Anti-IFX antibodies occurred in 14/62 children (23%) and 32/253 blood samples (12.6%) after a mean treatment time of 1084 days (range 73-3498). Infusion reactions occurred in 10/62 (16%) children during the treatment period. With continuation of IFX, anti-IFX antibodies disappeared in 7/14 children. In the bivariate analysis, the occurrence of anti-IFX antibodies was associated with younger age at IFX treatment start (mean age 7.01 vs 9.88 yrs, p = 0.003) and infusion reactions (OR 15.0), while uveitis as treatment indication was protective against development of anti-IFX antibodies (OR 0.17), likely because of higher IFX doses. In the multivariate logistic regression, all 3 covariates remained highly significant.
CONCLUSION
Anti-IFX antibodies occurred commonly at any time during IFX treatment. Anti-IFX antibodies were associated with younger age at IFX start, infusion reactions, and arthritis as treatment indication.
Infliximab (IFX) is a monoclonal tumor necrosis factor-α-inhibiting antibody used in children with refractory arthritis and uveitis. Immunogenicity is associated with a lack of clinical response and infusion reactions in adults; data on immunogenicity in children treated with IFX for rheumatic diseases are scarce. We aimed to describe the prevalence of anti-IFX antibodies and determine co-factors associated with anti-IFX antibodies in children with inflammatory rheumatic and ocular diseases.
METHODS
Consecutive children treated between August 2009 and August 2012 with IFX at our department were included. Blood samples were collected every 6 months before IFX infusion and tested for anti-IFX antibodies by radioimmunoassay. Patients' charts were retrospectively reviewed for clinical features and analyzed for associations with anti-IFX antibodies.
RESULTS
Anti-IFX antibodies occurred in 14/62 children (23%) and 32/253 blood samples (12.6%) after a mean treatment time of 1084 days (range 73-3498). Infusion reactions occurred in 10/62 (16%) children during the treatment period. With continuation of IFX, anti-IFX antibodies disappeared in 7/14 children. In the bivariate analysis, the occurrence of anti-IFX antibodies was associated with younger age at IFX treatment start (mean age 7.01 vs 9.88 yrs, p = 0.003) and infusion reactions (OR 15.0), while uveitis as treatment indication was protective against development of anti-IFX antibodies (OR 0.17), likely because of higher IFX doses. In the multivariate logistic regression, all 3 covariates remained highly significant.
CONCLUSION
Anti-IFX antibodies occurred commonly at any time during IFX treatment. Anti-IFX antibodies were associated with younger age at IFX start, infusion reactions, and arthritis as treatment indication.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.3899/jrheum.160072
- PMID 28089968
- Persistent URL
- https://sonar.ch/global/documents/47413
Statistics
Document views: 16
File downloads: